sorafenib has been researched along with Mole, Skin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennani-Lahlou, M; Escudier, B; Massard, C; Mateus, C; Robert, C; Soria, JC; Spatz, A | 1 |
| Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR | 1 |
2 other study(ies) available for sorafenib and Mole, Skin
| Article | Year |
|---|---|
[Eruptive nevi associated with sorafenib treatment].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Middle Aged; Nevus; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Young Adult | 2008 |
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult | 2009 |